The simultaneous positive data across three clinical programs (anzu-cel, IMA203CD8, IMA401) significantly de-risks Immatics' pipeline and supports the broad PRAME franchise thesis. Key catalysts to watch: SUPRAME Phase 3 interim/final analyses in 2026, IMA203CD8 RP2D determination in 2026, and IMA401/IMA402 combo data in 2027. The stock may re-rate as the probability of regulatory approval and commercial launch (targeted 2H 2027) increases.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $11.14entry
- T+1 · 6mo ago −9.87%α −10.02% · $10.04
- T+5 · 5mo ago −12.12%α −9.37% · $9.79
- T+20 · 5mo ago −9.07%α −7.77% · $10.13
- T+60 · 3mo ago −17.06%α −18.29% · $9.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipeline candidates presented at ASCO 2026: anzu-cel (IMA203) PRAME cell therapy in advanced melanoma showed 56% cORR, 14.6-month mDOR, 6.1-month mPFS, and 16.2-month mOS; IMA203CD8 PRAME cell therapy in gynecologic cancers showed 63% ORR (50% cORR) at clinically relevant doses with 4 complete responses; and IMA401 MAGEA4/8 bispecific in head and neck cancer showed 29% cORR and 8.8-month mDOR at RP2D. The filing also announced initiation of the IMA401/IMA402 combination cohort in sqNSCLC. These data collectively reinforce the clinical potential of Immatics' PRAME franchise across multiple solid tumor indications.
Key Facts
- Anzu-cel in advanced melanoma (n=33): 56% cORR, 14.6-month mDOR, 6.1-month mPFS, 16.2-month mOS; 42% of patients had deep responses (≥50% tumor reduction) with mPFS of 15.9 months
- IMA203CD8 in gynecologic cancers at clinically relevant doses (n=19): 63% ORR, 50% cORR, including 4 complete responses; 89% of confirmed responses ongoing with longest at 12 months
- IMA203CD8 in synovial sarcoma (n=12): 67% ORR, 64% cORR, including 1 complete response; mDOR 14.8 months at 31-month median follow-up
- IMA401 in head and neck cancer at RP2D (n=14): 29% cORR, 64% DCR, 8.8-month mDOR; 12-month OS rate 63%, 6-month PFS rate 43%
- IMA401/IMA402 combination cohort in sqNSCLC now enrolling; first data expected in 2027
- Phase 3 SUPRAME trial of anzu-cel in cutaneous melanoma ongoing; BLA submission expected 1H 2027, launch 2H 2027
- RP2D determination for IMA203CD8 expected in 2026
Financial Impact
No financial figures reported. Clinical data support potential multi-billion-dollar market opportunity across PRAME-positive cancers (>230K addressable patients in US/EU5 annually).
Risk Factors
- Phase 3 SUPRAME trial may fail to meet primary endpoint (PFS), delaying or preventing BLA submission
- Manufacturing scale-up for cell therapies (anzu-cel, IMA203CD8) may face capacity or cost challenges
- Competition from other TCR therapies, bispecifics, or checkpoint inhibitor combinations could limit market share
- Regulatory delays or safety signals in ongoing trials could derail timelines
- Dependence on HLA-A*02:01-positive patient population limits addressable market to ~41% US / 48% EU
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-008113 |
| Document: dp247360_6k.htm | 0000950103-26-008113 |
| Document: dp247360_ex9906.htm | 0000950103-26-008113 |
| Document: dp247360_ex9901.htm | 0000950103-26-008113 |
| Document: dp247360_ex9907.htm | 0000950103-26-008113 |
| Document: dp247360_ex9902.htm | 0000950103-26-008113 |
| Document: dp247360_ex9903.htm | 0000950103-26-008113 |
| Document: dp247360_ex9905.htm | 0000950103-26-008113 |
| Document: dp247360_ex9904.htm | 0000950103-26-008113 |
Track record
23 reports on IMTX
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers